Participants are therefore likely to be a heterogenous group of patients with breast cancer with varying treatment according to stage and subtype (eg, in addition to surgery, patients with DCIS may only receive radiation therapy, whereas patients with triple-negative or HER2-positive cancer are advised chemotherapy for several months) [95]. Here, ERBB2 is linked to cancer.